1. Home
  2. ADPT vs CHCO Comparison

ADPT vs CHCO Comparison

Compare ADPT & CHCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADPT
  • CHCO
  • Stock Information
  • Founded
  • ADPT 2009
  • CHCO 1957
  • Country
  • ADPT United States
  • CHCO United States
  • Employees
  • ADPT N/A
  • CHCO N/A
  • Industry
  • ADPT Biotechnology: Biological Products (No Diagnostic Substances)
  • CHCO Major Banks
  • Sector
  • ADPT Health Care
  • CHCO Finance
  • Exchange
  • ADPT Nasdaq
  • CHCO Nasdaq
  • Market Cap
  • ADPT 1.8B
  • CHCO 1.8B
  • IPO Year
  • ADPT 2019
  • CHCO N/A
  • Fundamental
  • Price
  • ADPT $12.54
  • CHCO $122.94
  • Analyst Decision
  • ADPT Strong Buy
  • CHCO Hold
  • Analyst Count
  • ADPT 8
  • CHCO 3
  • Target Price
  • ADPT $12.38
  • CHCO $132.33
  • AVG Volume (30 Days)
  • ADPT 2.1M
  • CHCO 102.7K
  • Earning Date
  • ADPT 08-05-2025
  • CHCO 07-22-2025
  • Dividend Yield
  • ADPT N/A
  • CHCO 2.59%
  • EPS Growth
  • ADPT N/A
  • CHCO 6.95
  • EPS
  • ADPT N/A
  • CHCO 8.30
  • Revenue
  • ADPT $205,216,000.00
  • CHCO $300,872,000.00
  • Revenue This Year
  • ADPT $24.39
  • CHCO $9.69
  • Revenue Next Year
  • ADPT $20.44
  • CHCO $1.71
  • P/E Ratio
  • ADPT N/A
  • CHCO $14.69
  • Revenue Growth
  • ADPT 21.60
  • CHCO 4.61
  • 52 Week Low
  • ADPT $3.98
  • CHCO $102.22
  • 52 Week High
  • ADPT $13.37
  • CHCO $137.28
  • Technical
  • Relative Strength Index (RSI)
  • ADPT 70.74
  • CHCO 47.44
  • Support Level
  • ADPT $12.62
  • CHCO $119.18
  • Resistance Level
  • ADPT $13.37
  • CHCO $124.49
  • Average True Range (ATR)
  • ADPT 0.81
  • CHCO 2.69
  • MACD
  • ADPT 0.22
  • CHCO -0.07
  • Stochastic Oscillator
  • ADPT 90.34
  • CHCO 36.54

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

About CHCO City Holding Company

City Holding Co is a financial holding company. The company conducts its principal activities through its wholly-owned subsidiary, City National Bank of West Virginia (City National). Through the bank, it provides banking, trust and investment management, and other financial solutions through its network of banking offices located in the states of West Virginia, Virginia, southeastern Ohio, and Kentucky. It offers various products and services such as overdraft facilities, savings accounts, credit cards and debit cards, loans for various purposes, investment advisory, securities brokerage, insurance products, and others. The company's business activities are currently limited to one reportable business segment, which is community banking.

Share on Social Networks: